Sotrovimab News and Research

RSS

Research highlights emergence of immune-evasive SARS-CoV-2 variants in immunocompromised patients

New research to be presented at next week's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) highlights the risk of new immune-evasive SARS-CoV-2 variants emerging in immunocompromised patients.

18 Apr 2024

Researchers characterize new SARS-CoV-2 BA.2.86 variant neutralization by monoclonal antibodies

Researchers used a SARS-CoV-2 spike protein-pseudotyped viral model to characterize BA.2.86 variant neutralization by monoclonal antibodies.

6 Sep 2023

Could neutralizing SARS-CoV-2 monoclonal antibodies pre-exposure prophylaxis be cost-effective in a population at risk for severe COVID-19?

A recent study evaluated the cost-effectiveness of monoclonal antibodies as pre-exposure prophylaxis (PrEP) for COVID-19.

11 Jul 2023

New study offers clues on how to future-proof covid-19 vaccines

New research examining how frequently our bodies produce broadly neutralizing antibodies (bnAbs) capable of thwarting a range of SARS-CoV-2 variants offers clues on the strategy tweaks that could potentially future-proof COVID-19 vaccines.

26 Jun 2023

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

Researchers highlighted the pace of development of COVID-19 therapies during the pandemic and the challenges that hinder the widespread availability of anticoronavirals.

8 May 2023

The virological characteristics of XBB.1.16

Researchers perform extensive multiscale investigations to explore virological characteristics of the SARS-CoV-2 Omicron XBB subvariant, XBB.1.16.

12 Apr 2023

mAb therapy reduces risk of hospitalization and death against Alpha, Delta, and Omicron variants

Researchers assess the efficacy of monoclonal antibodies in treating COVID-19 caused by different viral variants.

6 Apr 2023

Real-world data on the effectiveness of Sotrovimab as a prophylactic against COVID-19

In a recent study posted in the medRxiv* preprint server, scientists assessed the efficacy of sotrovimab for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) treatment.

16 Mar 2023

Bispecific antibody shows improved efficacy against SARS-CoV-2 variants

Researchers from The University of Texas MD Anderson Cancer Center have developed fully human bispecific antibodies, as revealed in a recent study. These antibodies can bind to two distinct epitopes of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and have demonstrated the ability to neutralize various strains of the virus, including the Omicron variant.

14 Mar 2023

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

Researchers used a non-human primate model to show that Sotrovimab, a commercial mAb also known as Xevudy, was fully effective against SARS-CoV-2 Omicron BA.5 sub-lineage and its derivatives, such as BQ.1.1.

17 Feb 2023

Omicron BQ and XBB subvariants most resistant viruses to monoclonal antibodies

A recent study examines the neutralization of SARS-CoV-2 Omicron sub-variants by sera from boosted individuals and those with breakthrough infection.

13 Feb 2023

The relationship between natural plant extracts and SARS-CoV-2

Researchers explored plants as an extensive resource of molecules with potential therapeutic action against SARS-CoV-2 and debunked misconceptions.

3 Feb 2023

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

Researchers explored how mutations in emergent SARS-CoV-2 variants affect viral function, human immunity, and recognition by therapeutic antibodies.

19 Jan 2023

Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine doses

In a recent correspondence published in The Lancet Infectious Diseases journal, researchers in Germany assessed the neutralization sensitivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB.1 lineage.

9 Jan 2023

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

Researchers investigated the efficacy of ritonavir and nirmatrelvir combination treatment in reducing the risk of COVID-19 severity outcomes such as hospital admissions and deaths when administered during the initial period of SARS-CoV-2 infections.

16 Dec 2022

Characterization of immune evasion and cell entry for new variants: BQ.1.1, XBB.1, and BR.2.1

In a recent study posted to the medRxiv* preprint server, researchers in Australia and Switzerland evaluated the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in community-based settings of the United States (US).

13 Dec 2022

New method for isolating Omicron subvariant and evaluating resistance to therapeutic and vaccine-elicited antibodies

Researchers demonstrated a viral amplification procedure to isolate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants.

21 Nov 2022

Among US veterans with COVID-19, few used antivirals or monoclonal antibodies

In a recent study published in the journal JAMA Network, researchers in the United States investigated factors that restricted the use of antivirals directed at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States (US) between January and February 2022.

16 Nov 2022

Outcomes from an Australian COVID-19 virtual ward during Omicron wave

In a recent study posted to the medRxiv* preprint server, researchers in Australia characterized hospitalization volumes, patient epidemiological and clinical outcome data of patients admitted to virtual wards during the predominance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) BA.1 sub-VOC and the Omicron BA.2 sub-VOC.

8 Nov 2022

Researchers identify 55 broadly reactive monoclonal antibodies to betacoronaviruses

In a recent study published in the journal Cell Host & Microbe, researchers pursued novel approaches that could help find monoclonal antibodies (mAbs) broadly targeting coronaviruses (CoVs), especially genera beta CoVs.